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he use of atypical neuroleptics in psychotic dis-
orders has steadily increased since 1989,and atypical neu-
roleptics have become the first line of treatment for psy-
chotic disorders.Since the marketing of clozapine in 1989
in the USA, several other atypical neuroleptics have
become available to clinicians there,and this has extended
and diversified the prescriptions of atypical neuroleptics.
However,no newer atypical neuroleptic has yet shown
greater efficacy than clozapine.In addition,many patients
have improved only partially with these newer atypical
neuroleptics.Clinicians often face difficult choices when
patients do not respond or partially respond to these
newer atypicals. Several strategic possibilities are then
available to clinicians: (i) increasing the dosage of the
antipsychotic;(ii) switching to another neuroleptic;(iii)
augmenting treatment with a mood stabilizer; and (iv)
using polypharmacy (meaning adding a second antipsy-
chotic medication).Before adding any other medication,
or changing to another neuroleptic,a fundamental ques-
tion should be answered:has the current neuroleptic been
optimally used? This question can be divided into two dif-
ferent questions: has the length of the medication trial
been long enough,and has the patient received an opti-
mal dosage?
In this presentation,we will focus on the second question:
what is the optimal dosage for the atypical neuroleptics?
We will limit the neuroleptics to the atypical agents cur-
rently available in the USA (clozapine,risperidone,olan-
zapine, quetiapine, ziprasidone, and aripiprazole), and
thus we will not discuss dosing issues regarding other
atypicals such as sertindole or amisulpride.
Lessons from typical neuroleptics
The issue of optimal dosage with typical neuroleptics has
been the focus of frequent debates.For example,in the
seventies,very high doses of haloperidol were routinely
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Atypical neuroleptics have become the first line of treat-
ment for psychotic disorders, but some questions remain:
what are their optimal dosages and is more medication
more efficacious? For clozapine, it is recommended to aim
for a plasma level above 350 ng/mL for nonresponders
and partial responders. It should be specified that this
plasma level should be obtained exactly 12 h after the last
dose. For risperidone, optimal daily doses range between
4 and 8 mg, and there is no indication that a higher dose
would bring additional improvement. For olanzapine, a
quite different situation is encountered. There is a good
indication that daily doses of 30 and 40 mg can increase
clinical response. It appears that plasma levels above 23
ng/mL may predict response. For quetiapine, reports on
the utility of dosages greater than 800 mg/day are anec-
dotal at this point, and more studies should be conducted.
For ziprasidone, dosages above 40 mg/day should be used,
but daily doses above 200 mg have not yet been system-
atically investigated.
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used.However,it became clear that high doses can lead
to more side effects and particularly to more extrapyra-
midal side effects (EPS).In the nineties,an opposite trend
arose:it was considered that much lower doses than 30
mg/day were sufficient to obtain optimal efficacy.This was
supported by positron emission tomography (PET) stud-
ies that showed that small daily doses such as 5 mg were
sufficient to obtain more then 60% blockade of the
dopamine D2 receptors in the basal ganglia. Conse-
quently,the average daily dosage of typical neuroleptics
has decreased in clinical settings and in clinical research
trials (eg,when haloperidol is used as a comparative treat-
ment arm). One remaining issue is to identify patients
who may need higher doses. Although it is commonly
accepted that fast metabolizers need higher doses,there
is very little evidence to support the use of high doses in
other circumstances. Clinicians tend to increase neu-
roleptic doses,and sometimes up to high doses,for break-
through symptoms and for a partial response.One study
1
found that patients who receive high doses of typical neu-
roleptics tend to show a more severe course of illness and
more persistent symptoms,and some had a history of vio-
lence or regressed behavior.
What doses do clinicians prescribe?
In the USA, clinical use of atypicals began in 1989 with
clozapine.At that time,it was commonly accepted that the
average daily dose should be around 500 to 600 mg.It is of
note that, in the last 5 years, publications report that in
Europe the average daily dose of clozapine has been much
lower (around or below 300 mg),and at the same time,the
average daily dose of clozapine has decreased in the USA,
as seen in psychiatric hospitals operated by the State of
New York (Table I).
2 State hospitals in the USA are ded-
icated to the treatment of people with mental illness who
have minimal or no insurance,and who need longer hos-
pital stays.For these reasons,patients in state hospitals are
mostly those with schizophrenia or schizoaffective disor-
der,and who also have frequent relapses,or who do not
show a good and fast response to therapy,and are thus the
most challenging patient population to treat.The average
daily doses of clozapine and risperidone have decreased
in the last 5 years,while the average daily dose of olanza-
pine has increased,almost reaching the maximal recom-
mended dose.This current practice does not seem specific
to New York State.Stahl
3 reported that,in California,the
average daily dose in 2002 was 4.0 mg for risperidone,20.5
mg for olanzapine,and 316 mg for quetiapine (for patients
aged 18 to 44).Although the patient populations were not
quite comparable between these two reports,it appears
that clinicians use a lower daily dose of risperidone than
before,whereas they use higher doses of olanzapine.
Evidence for an optimal dose of 
atypical neuroleptics
For all atypicals,studies have shown that very low doses
are no better than placebo,so the question of finding the
optimal dose can be summarized as:is more medication
more efficacious? There are two ways to measure the
quantity of medication each patient receives:daily dose
and plasma level.Usually,when plasma levels are studied,
the question that researchers try to answer is: is there a
drug plasma level that should be reached in order to
obtain an optimal response? To answer this,a specific sta-
tistical tool is used:the receiver operating characteristics
(ROC) curves.These curves are obtained by ranking each
patient from the highest plasma level to the lowest plasma
level.Each case is then plotted on a graph:the y axis rep-
resents the cumulative percentage of responders (which is
also the sensitivity of the cutoff point),while the xaxis rep-
resent the cumulative percentage of nonresponders (which
will give the specificity of the cutoff point,by subtracting
Table I. Recommended daily doses of neuroleptics, and neuroleptic doses used in New York State Hospitals. FDA, Food and Drug Administration. Data
taken from reference 2.
Antipsychotic Daily doses recommended  New York State Hospitals
by the FDA (mg) Mean daily dose used (mg)
1997 (1st quarter) 2001 (3rd quarter)
Clozapine 300-450; maximum: 900 586.3 (N=845) 494.7 (N=851)
Risperidone 4-8; maximum: 16 7.1 (N=1320) 4.9 (N=1552)
Olanzapine 10-15; maximum: 20 15.6 (N=1057) 18.9 (N=1662)
Quetiapine  300-500; maximum: 800 Not available 518.4 (N=782)
Ziprasidone 40-160; maximum: 200 Not available 132.4 (N=129)this number from 1). From the curve, a cutoff point is
determined, and a chi-square analysis is undertaken to
determine whether the percentage of responders among
patients with a plasma level above the cutoff point is sig-
nificantly different from the rate of responders with a
plasma level under the cutoff point.We will now review
the evidence for high dosing for each atypical neuroleptic.
Clozapine 
Several studies
4-10 have tried to determine a threshold for
the clozapine plasma level,above which a response could
be predicted (Table II).Comparison between these stud-
ies is made difficult as they vary greatly in their method-
ologies.For example,some used a fixed dose,while oth-
ers did not (which leads to a lower percentage of
responders in the high doses,and thus makes it difficult
to identify a threshold).However,it can be concluded that
350 ng/mL can be considered as a plasma threshold for
optimal clozapine therapy. Moreover, several remarks
need to be made:
• 350 ng/mL is not a “magical”number.A good percent-
age of patients do improve even with plasma levels
lower than 350 ng/mL.This means that for patients who
do not respond or partially respond to clozapine,and
who have a plasma level below 350 ng/mL, efforts
should be made to obtain a clozapine plasma level
above 350 ng/mL,before establishing that these patients
are clozapine nonresponders.
•The dosage of clozapine plus norclozapine does not add
precision in the determination of a threshold compared
with clozapine plasma level alone.
• Clozapine plasma levels vary greatly between individu-
als.This is quite important, and some patients with a
daily dose of 900 mg may not achieve a plasma level of
350 ng/mL,while some patients even with a low daily
dose may show a plasma level a good deal higher than
350 ng/mL.
•A higher plasma level is associated with a higher risk of
seizures.
•The dosing schedule should be taken into consideration.
As clozapine has an average half-life of 12 h,a daily dos-
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Table II. Studies of clozapine plasma levels and response rates. BPRS, Brief Psychiatric Rating Scale; NA, not available; NS, not significant; PANSS, Positive
and Negative Syndrome Scale.
Reference N Duration Fixed dosage Mean dosage Criteria for Cutoff  Response rate Sensitivity/ Remarks




4 29 4 400 384±42 BPRS  350  64% vs 22% 64%/78% Dose
1991 ≥20% P=0.03 given at
bedtime
Hasegawa 59 26 No 444±270 BPRS 370 73% vs 38% 53%/73% Level at
et al,
5 1993 ≥20% P=0.01 D29 to
D2288
Potkin et al,
6 58 12 400 for 6  Then 400 BPRS 420 60% vs 8% at W4 74%/NA Frequency?
1994 weeks or 800 ≥20% 73% vs 23% at W12
Kronig et al,
7 45 6 500 for 3 623±203 BPRS 350 55% vs 20% 80%/54% Dose
1995 weeks ≥20% P<0.04 given
BID
VanderZwaag  56 12 NA Plasma: BPRS >200-300 60% vs 39% NS BID or
et al,




9 45 12 No 309±63 BPRS 350 62% vs 21% 72%/70% BID or
2000 ≥20% P<0.02 TID
Llorca et al,
10 37 18 No 486 PANSS 550 NS 64%/51% QD or BID
2002 ≥20% (at 6 PM
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ing schedule of 400 mg at night will lead to a higher
plasma level than a dosing schedule of 200 mg twice a
day,even if levels are drawn 12 h after the last dose in
both cases.This may explain some discrepancies between
the results of the studies examining plasma levels.
• In all these studies,blood was drawn 12 h after the last
clozapine dose. Clinicians should make sure that
plasma levels are checked exactly 12 h after the last
clozapine dose.Again, as the half-life of clozapine is
around 12 h, a plasma level of 350 ng/mL at 12 h, will
drop to 310 ng/mL at 13 h.Although this might not be
a difficult problem to resolve with inpatients,it can be
quite a challenge with outpatients.
Risperidone
Risperidone was released commercially in the USA in
1994.Two major studies,one North American
11 and one
European,
12 compared different doses of risperidone.
Both favored mid-range daily doses:6 mg for the North
American study,and 4 and 8 mg in the European study.
These two studies did not give any indication that higher
doses would bring a better response rate.The absence of
a dose–response relationship for risperidone has been
further confirmed by biological studies. One study
13
could not find any significant correlation between the
plasma concentration of risperidone and clinical
response.However,it has been shown that higher doses
of risperidone lead to a higher frequency of EPS, and
thus they lose the one great advantage that atypicals
have brought,ie,the low frequency of EPS.
Olanzapine
Olanzapine has been commercially available in the USA
since 1996.As we have seen,clinicians tend to use higher
and higher daily doses of olanzapine.However,one would
like to have evidence from clinical trials showing that
patients, or at least some patients, improve to a greater
degree with high doses.Several lines of evidence can be
found in the literature.First,in their pivotal randomized
clinical trial, Beasley et al
14 found that 48% of patients
improved with a mean daily dose of 5 mg, while 58%
improved with 10 mg and 66% with 15 mg.This leads to
the following question:will more patients improve as we
continue to increase the dosage of olanzapine? Several
case reports have been published describing a better
response with an increment of olanzapine dosage above
20 mg/day.A recently published double-blind study
15 has
shed more light on this issue.In the first 8 weeks of this
study,patients received a fixed daily dose of clozapine (500
mg),olanzapine (20 mg),risperidone (8 mg),or haloperi-
dol (20 mg). In the subsequent 6 weeks, doses were
adjusted clinically,although clinicians remained blind to
medication.At the end of the study,the average daily dose
was 30 mg for olanzapine,530 mg for clozapine,12 mg for
risperidone, and 26 mg for haloperidol. Interestingly
enough,only the patients who were on olanzapine con-
tinued to improve as their dose was increased.This tends
to show that doses of olanzapine above the maximal rec-
ommended dose may be beneficial for optimizing olanza-
pine treatment.This finding awaits replication.
One study
16 tried to determine a plasma level threshold for
olanzapine using the ROC methodology outlined earlier.
In this study,several fixed arms were used,and a cut-off
point of 23 ng/mL was shown to be an olanzapine plasma
level threshold in order to obtain an optimal response.
Quetiapine
Quetiapine was released commercially in the USA in
1997. Quetiapine has a rather unique receptor profile.
Like clozapine, quetiapine is a low-potency dopamine
D2 blocker,and one study
17 showed that quetiapine leads
to transient high D2 occupancy,which decreases to very
low levels after 12 h.Two major studies
18,19 compared
various daily doses of quetiapine from 75 mg to 750 mg.
It appears that doses above 75 mg are necessary to
obtain a response superior to placebo.These studies did
not give any indication of a clear dose–response rela-
tionship.However,some case reports have indicated that
a daily dose above 800 mg brought a better response for
some symptoms.For this reason,some clinical trials com-
paring usual doses of quetiapine with higher than rec-
ommended daily doses (up to 1200 mg) are planned.
Ziprasidone
Ziprasidone was released commercially in the USA in 2001.
Two placebo-controlled studies compared different daily
doses of ziprasidone in acute schizophrenia.The first one
20
compared ziprasidone 40 mg/day with ziprasidone 120
mg/day.A daily dose of 40 mg led to a 37% response rate,
and a daily dose of 120 mg to a response rate of 49%.In the
second study,
21 29% of the patients improved with a daily
dose of 80 mg, versus 31% of the patients on 160 mg. Ineach of the two pivotal trials,the higher dose of ziprasidone
resulted in a greater efficacy than the lower dose.Dosages
greater than 40 mg/day are recommended.This was con-
firmed in a 1-year,placebo-controlled clinical trial.
22After
1 year,43% of patients on 40 mg/day had relapsed versus
35% of the patients on 80 mg/day,and 36% of the patients
on 160 mg/day. Systematic trials using dosages of 200
mg/day have not yet been reported.It is possible that higher
doses of ziprasidone may lead to higher rates of response.
Aripiprazole 
Aripiprazole has been available in the USA since
November 2002.For this reason,experience is very lim-
ited.The recommended daily dosage is from 10 to 30 mg.
From the phase 3 clinical trials, high dosages of 30
mg/day were no more effective than lower dosages of 10
or 15 mg/day. It will be interesting to see whether clini-
cal usage of this compound will confirm this finding.The
efficacy of dosages above 30 mg/day is not known.
Conclusions
The determination of an optimal dosage for each atyp-
ical neuroleptic is an important issue for the clinical
treatment of patients with schizophrenia.For clinicians,
it is linked to another important question:when can we
consider that a patient has not responded to a specific
antipsychotic? In this presentation, it appeared that (i)
for most atypical neuroleptics,little is known;and (ii) for
each atypical neuroleptic, a different answer should
apply.
For clozapine, it is recommended to aim for a plasma
level above 350 ng/mL for nonresponders and partial
responders.It should be specified that this plasma level
should be obtained exactly 12 h after the last dose. For
risperidone, optimal dosages range between 4 and 8
mg/day, and there is no indication that a higher dose
would bring additional improvement. For olanzapine, a
quite different situation is encountered.There is good
indication that dosages of 30 and 40 mg/day can increase
clinical response.It appears that plasma levels above 23
ng/mL may predict response.For quetiapine,reports on
the utility of dosages greater than 800 mg/day are anec-
dotal at this point, and more studies should be con-
ducted. For ziprasidone, dosages above 40 mg/day
should be used, but daily doses above 200 mg have not
yet been systematically investigated. For aripiprazole,
experience is very limited, but it seems that daily
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Optimización de la dosis en monoterapia de
neurolépticos atípicos
Los neurolépticos atípicos han llegado a ser el tra-
tamiento de primera línea para los trastornos psi-
cóticos, pero persisten algunas preguntas: ¿cuáles
son sus dosis óptimas? y ¿la mayor cantidad de
medicación es más eficaz? Para la clozapina se reco-
mienda alcanzar un nivel plasmático por sobre los
350 ng/mL en los no respondedores o respondedo-
res parciales. Se debe especificar que este nivel plas-
mático se debe obtener exactamente 12 horas des-
pués de la última dosis. Para la risperidona, el rango
de dosis óptima es entre 4 mg y 8 mg y no hay indi-
cación que una dosis mayor produzca una mejoría
adicional. Para la olanzapina se ha encontrado una
situación completamente diferente. Existe un buen
fundamento para que dosis de 30 mg y 40 mg pue-
dan aumentar la respuesta clínica. Al parecer los
niveles plasmáticos por sobre 23 ng/mL pueden pre-
decir la respuesta. Para la quetiapina los datos dis-
ponibles hasta el momento sobre la utilidad de
dosis mayores a 800 mg/día son anecdóticos, y se
requiere que se realicen más estudios. Para la zipra-
sidona se deben usar sobre 40 mg/día, pero dosis
diarias sobre 200 mg no se han investigado siste-
máticamente hasta la fecha.
Optimisation de la posologie d’une 
monothérapie neuroleptique atypique
Les neuroleptiques atypiques sont devenus le trai-
tement de choix des troubles psychotiques, mais
quelques questions persistent : quelle est leur poso-
logie optimale ? Une posologie supérieure est-elle
plus efficace ? En ce qui concerne la clozapine, viser
une concentration plasmatique au-dessus de 350
ng/ml est recommandé chez les non-répondeurs et
les sujets partiellement répondeurs, en spécifiant
que ces concentrations doivent être obtenues exac-
tement 12 heures après la dernière dose. Pour la ris-
péridone, les doses optimales se situent entre 4 et
8 mg/j, et rien n’indique qu’une posologie plus éle-
vée apporterait une amélioration supplémentaire.
On est confronté à une situation tout à fait diffé-
rente avec l’olanzapine. Tout indique que des poso-
logies entre 30 et 40 mg/j peuvent augmenter la
réponse clinique. Il semble qu’on puisse prévoir une
réponse avec des concentrations plasmatiques au-
dessus de 23 ng/ml. Pour la quetiapine, l’utilité de
doses supérieures à 800 mg/j n’est attestée que de
façon anecdotique actuellement, et plus d’études
sont nécessaires. Pour la ziprasidone, il faut utiliser
des doses supérieures à 40 mg/j, mais des doses
quotidiennes supérieures à 200 mg n’ont pas été
encore systématiquement étudiées.
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